Diana Canto-Sims, OD, owner of Buena Vista Optical, discusses how Meta's donation of free AI glasses to blind veterans could close longstanding access gaps in low vision care—and where voice-command wearables fit alongside traditional rehabilitation tools.
A large real-world cohort study finds OSA is associated with elevated glaucoma risk, though whether positive airway pressure therapy itself plays a role remains unclear.
Bayer acquired Perfuse Therapeutics and its experimental endothelin-blocking eye implant PER-001, and partnered with AI firm Iambic Therapeutics to accelerate small molecule drug discovery.
Their conversation covers a holistic, cross-specialty approach to ocular surface disease and the unmet need driving a new model of dry eye care in Ireland.
ARPA-H funds OCULAB to build tear-duct sensors that track biomarkers in real time and microdose drugs, transforming dry-eye and systemic care.
The newly formed biotech will use the financing to push MMT-205, a bispecific antibody that directly activates Tie2 while inhibiting VEGF, toward IND-enabling studies, with first-in-human trials slated for 2027.
Atsena reported that, since enrollment opened in May 2026, it has already accrued approximately 10% of the pivotal cohort and expects the pace to accelerate as additional sites across North America and Europe are activated.
NCX 470 glaucoma drop gains China regulatory encouragement, clearing path for near-term filings and expanding commercial upside beyond the US.
A retrospective study finds that direct selective laser trabeculoplasty significantly lowers intraocular pressure, with the greatest benefit seen in treatment-naive eyes.
A prospective pilot series finds Keraring implantation cuts refractive cylinder by 61% in non-ectatic corneas, opening a new conversation about ICRS indications.
The 2-day program at the Gaylord Opryland Resort will bring together established and emerging eye care leaders for sessions on leadership development, artificial intelligence, inclusion, and career growth.
Douglas D. Koch, MD, and Karolinne Maia Rocha, MD, PhD, discuss the optics behind enhanced monofocal lenses, patient selection, and how to set expectations.
A balanced mix of AI-generated and smartphone-captured images eliminated the domain-specific failures seen with single-source training
The resubmission is considered a Class 1 submission and has a current PDUFA target action date of July 29, 2026.
Belite Bio has completed its rolling NDA submission to the FDA for tinlarebant, a potential first approved treatment for Stargardt disease type 1.
Optical coherence tomography angiography found distinctive microvascular signatures in the retinal layers associated with various stages of decline in cognition.
A midyear recap of the cataract-related news Ophthalmology Times has covered in 2026
Host Deborah Ristvedt, DO, welcomes Vance Thompson, MD, to discuss how prioritizing people has shaped the culture and growth of Vance Thompson Vision.
Step-by-step prompting boosts multimodal AI accuracy on bilingual ophthalmology vignettes with images—but weak subspecialty and image-reading skills remain.
A case report describes image-guided surgical excision combined with adjunctive cryotherapy and a single anterior chamber methotrexate injection, with no recurrence at 10 months.
In part 2 of a 2-part Q&A, John Berdahl, MD, weighs in on AI-driven IOL power calculation in challenging eyes, best practices for reducing posterior capsule opacification, and how surgical mission work abroad has shaped his approach in the OR.
Three-year gene therapy data, an FDA reversal in wet AMD, light-powered dry eye treatment, a new macular supplement, and progress in childhood glaucoma—our review breaks down the 5 May 2026 stories that matter.
The update introduces a 250 kHz scan speed for OCT Angiography combined with enhanced TruTrack Active Eye Tracking, as well as new multimodal imaging capabilities, including the Green Autofluorescence Module
The FDA approved the TECNIS PureSee IOL (model ZEN00V) on March 12, 2026.
New phase 3 trial tests rhNGF eye drops for persistent corneal epithelial defects, aiming for full healing and a first approved PCED therapy.
Alkeus Pharmaceuticals has dosed the first participant in the phase 3 NORTHSTAR trial of oral gildeuretinol for Stargardt disease, a condition with no approved treatments.
Finding satisfaction in ocular research—considerations about AI and enhanced datasets.
A newly developed diagnostic system, CaptureTumor (CaT), driven by artificial intelligence (AI) and designed specifically for smartphone deployment, achieved diagnostic accuracy comparable to that of a specialist-graded slit-lamp evaluation” for detecting rare ocular surface malignancies.
LENZ Therapeutics licenses FDA-approved presbyopia drop to Everest Medicines for Greater China; NDA under review by NMPA with approval anticipated in Q1 2027
In part 1 of a 2-part Q&A, John Berdahl, MD, discusses the widening global cataract surgical gap and examines emerging evidence linking cataract extraction to a reduced risk of dementia.
